Back |
home / stock / kalv / kalv message board
Subject | By | Source | When |
---|---|---|---|
New buyer? They're not being bought, they're merging | Toxic Avenger | investorshub | 11/18/2016 7:59:44 PM |
Somethings fishy going on here. Why the sudden | beginneer | investorshub | 11/18/2016 7:46:37 PM |
Fun while it lasted. ;-) | Toxic Avenger | investorshub | 11/16/2016 7:12:06 PM |
Big bounce today. Anyone know why? | Toxic Avenger | investorshub | 11/14/2016 6:04:22 PM |
$700k / month for a company that has | Toxic Avenger | investorshub | 11/09/2016 1:47:26 AM |
Looks like an attempt to prevent the merger | Toxic Avenger | investorshub | 11/05/2016 10:18:24 AM |
Looks like an attempt to prevent the merger | Toxic Avenger | investorshub | 11/05/2016 10:18:23 AM |
Sadly, I don't think so. | Toxic Avenger | investorshub | 11/03/2016 11:51:28 PM |
Any idea what the general consensus among shareholders | MSparks6 | investorshub | 11/03/2016 11:49:15 PM |
LOL, $CBYL declined back to $0.49 again! The | Value_Investor | investorshub | 10/25/2016 4:12:06 PM |
Can you please stick that post#376 to the | Value_Investor | investorshub | 10/24/2016 3:28:12 PM |
Get him on the phone $NOW! | Toxic Avenger | investorshub | 10/22/2016 11:37:50 PM |
A New Merger proposal to the CEO of | Value_Investor | investorshub | 10/22/2016 10:44:58 PM |
$CBYL declined to $0.4984 so far from yesterday's | Value_Investor | investorshub | 10/21/2016 2:32:33 PM |
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable...